Pomerantz Law Firm Launches Investigation for Capricor Therapeutics Investors
In a recent development that has raised eyebrows in the investment community, Pomerantz Law Firm has initiated an investigation aimed at uncovering possible claims on behalf of investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation centers on allegations of securities fraud and other unlawful business practices that may involve Capricor's officers and directors. The implications of this investigation unfold as the company faces significant challenges regarding its investigational drug, deramiocel, intended for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy.
On May 5, 2025, Capricor made headlines when it disclosed that the U.S. Food and Drug Administration (FDA) had signaled its intent to convene an advisory committee meeting concerning the Biologics License Application (BLA) for deramiocel. This announcement was seen as a critical step toward obtaining full approval for the drug. However, the positive anticipation quickly dissipated, as the subsequent day marked a drastic drop in Capricor's stock price, which plunged by $3.00 per share—equating to a staggering 29.13% decline, closing at $7.30 per share.
Compounding this situation, on June 20, 2025, the publication STAT reported disturbing news: the newly appointed head of the FDA's relevant unit had canceled the planned advisory committee meeting amid growing uncertainties regarding the drug's efficacy and safety. Following this announcement, Capricor's stock faced another severe blow, plummeting further by $3.68 (30.82%) to close at $8.26 per share. These steep declines have understandably prompted investor concern and scrutiny surrounding the company’s disclosures and business practices.
Pomerantz LLP, a well-respected law firm with offices across key cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has built a strong reputation for its expertise in corporate, securities, and antitrust class litigation. Founded over 85 years ago by Abraham L. Pomerantz, a pioneering figure in the class action bar, the firm has fought valiantly for the rights of those affected by securities fraud, breaches of fiduciary duty, and various instances of corporate wrongdoing. In this latest investigation, they aim to determine if Capricor and its leadership indeed engaged in deceptive practices that could have jeopardized shareholder interests.
The firm’s proactive stance serves as a reminder to investors of the risks associated with holdings in companies facing regulatory scrutiny and pending drug approvals. Investors who believe they might be affected by the developments at Capricor are encouraged to reach out to Danielle Peyton of Pomerantz LLP for further guidance and support in potentially joining a class action lawsuit.
As the landscape surrounding Capricor Therapeutics continues to evolve, it will be crucial for current and future investors to stay informed about ongoing investigations, announcements from the company, and any implications regarding stock performance. The unfolding scenario presents not only challenges for Capricor but also broader lessons for the investment community about due diligence and the importance of maintaining vigilant oversight when it comes to companies navigating the complexities of the biopharmaceutical industry. Investors interested in exploring the prospects of this case further can visit pomlaw.com for more information about the firm’s approach and past successes in securities class actions.
On May 5, 2025, Capricor made headlines when it disclosed that the U.S. Food and Drug Administration (FDA) had signaled its intent to convene an advisory committee meeting concerning the Biologics License Application (BLA) for deramiocel. This announcement was seen as a critical step toward obtaining full approval for the drug. However, the positive anticipation quickly dissipated, as the subsequent day marked a drastic drop in Capricor's stock price, which plunged by $3.00 per share—equating to a staggering 29.13% decline, closing at $7.30 per share.
Compounding this situation, on June 20, 2025, the publication STAT reported disturbing news: the newly appointed head of the FDA's relevant unit had canceled the planned advisory committee meeting amid growing uncertainties regarding the drug's efficacy and safety. Following this announcement, Capricor's stock faced another severe blow, plummeting further by $3.68 (30.82%) to close at $8.26 per share. These steep declines have understandably prompted investor concern and scrutiny surrounding the company’s disclosures and business practices.
Pomerantz LLP, a well-respected law firm with offices across key cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has built a strong reputation for its expertise in corporate, securities, and antitrust class litigation. Founded over 85 years ago by Abraham L. Pomerantz, a pioneering figure in the class action bar, the firm has fought valiantly for the rights of those affected by securities fraud, breaches of fiduciary duty, and various instances of corporate wrongdoing. In this latest investigation, they aim to determine if Capricor and its leadership indeed engaged in deceptive practices that could have jeopardized shareholder interests.
The firm’s proactive stance serves as a reminder to investors of the risks associated with holdings in companies facing regulatory scrutiny and pending drug approvals. Investors who believe they might be affected by the developments at Capricor are encouraged to reach out to Danielle Peyton of Pomerantz LLP for further guidance and support in potentially joining a class action lawsuit.
As the landscape surrounding Capricor Therapeutics continues to evolve, it will be crucial for current and future investors to stay informed about ongoing investigations, announcements from the company, and any implications regarding stock performance. The unfolding scenario presents not only challenges for Capricor but also broader lessons for the investment community about due diligence and the importance of maintaining vigilant oversight when it comes to companies navigating the complexities of the biopharmaceutical industry. Investors interested in exploring the prospects of this case further can visit pomlaw.com for more information about the firm’s approach and past successes in securities class actions.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.